Chronic inflammation plays a critical role in the onset and progression of diabetes, highlighting the role of inflammation and the immune system in diabetes. In type 1 diabetes, autoimmune destruction of pancreatic beta cells results from dysregulated immune responses, while in type 2 diabetes, low-grade systemic inflammation contributes to insulin resistance. Pro-inflammatory cytokines such as TNF-α and IL-6 disrupt insulin signaling pathways, exacerbating metabolic dysfunction. Emerging therapies targeting inflammatory pathways, including immune-modulating drugs and anti-inflammatory diets, offer new possibilities for intervention. Research continues to explore how immune modulation can delay disease onset and improve long-term outcomes in diabetes management.
Title : Diabetes reduction (pre-diabetes and type 2) with integrative medicine
F Buck Willis, IUHS School of Medicine, Saint Kitts and Nevis
Title : Adipose MTP deficiency protects against hepatic steatosis by upregulating PPAR activity
Sujith Rajan, NYU Long Island School of Medicine, United States
Title : Does winter melon (Benincasa hispida) improves nutritional values and ameliorating glycaemic parameters?
Wan Rosli Wan Ishak, Universiti Sains Malaysia, Malaysia
Title : Clinical applications of monitoring unmethylated insulin cfDNA associated with beta-cell death for diabetes and metabolic diseases
Clifford Morris, Kihealth, United States
Title : Diabetes and migration: Impact of internal displacement on the prevalence and management of diabetes in Les Cayes, South Haiti (2022-2024)
Berger Saintius, Field Epidemiology Training Program (FETP), Haiti
Title : Correlation between food insecurity and diabetes in the commune of Les Cayes (2021-2024)
Djeamsly Salomon, Field Epidemiology Training Program (FETP), Haiti